Correction to: miR-200c Inhibits invasion, migration and proliferation of bladder cancer cells through down-regulation of BMI-1 and E2F3 (Journal of Translational Medicine, (2014), 12, 1, (305), 10.1186/s12967-014-0305-z);MiR-200c Inhibits invasion, migration and proliferation of bladder cancer cells through down-regulation of BMI-1 and E2F3

Journal of Translational Medicine

Volumn 12, Issue 1, 2014, Pages

  Liu, Lei ^a   Qiu, Mingning ^a   Tan, Guobin ^a   Liang, Ziji ^a   Qin, Yue ^a   Chen, Lieqian ^a   Chen, Hege ^a   Liu, Jianjun ^a  

^a GUANGDONG MEDICAL UNIVERSITY   (China)

Author keywords

Bladder cancer cells; BMI 1; E2F3; MiR 200c

Indexed keywords

BMI1 PROTEIN; LENTIVIRUS VECTOR; LUCIFERASE; MICRORNA 200C; NERVE CELL ADHESION MOLECULE; PROTEIN P14; PROTEIN P16; TRANSCRIPTION FACTOR E2F3; UVOMORULIN; BMI1 PROTEIN, HUMAN; CADHERIN; CDH1 PROTEIN, HUMAN; E2F3 PROTEIN, HUMAN; MICRORNA; MIRN200 MICRORNA, HUMAN;

3' UNTRANSLATED REGION; ARTICLE; BINDING SITE; BLADDER CANCER; BLADDER CANCER CELL LINE; BLADDER CARCINOGENESIS; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; GENE FUNCTION; GENE MUTATION; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRACELLULAR SIGNALING; LUCIFERASE ASSAY; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; WILD TYPE; BLADDER TUMOR; CELL MOTION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; METASTASIS; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PATHOLOGY; TUMOR CELL LINE; TUMOR INVASION; UPREGULATION;

BASE SEQUENCE; CADHERINS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DOWN-REGULATION; E2F3 TRANSCRIPTION FACTOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; MOLECULAR SEQUENCE DATA; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; POLYCOMB REPRESSIVE COMPLEX 1; UP-REGULATION; URINARY BLADDER NEOPLASMS;

EID: 84920761644     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/s12967-022-03299-6     Document Type: Erratum

References (53)

1. Siegel R, Ma J, Zou Z, Jemal A: Cancer statistics, 2014. CA Cancer J Clin 2014, 64:9-29.
2. Dreicer R: Advanced bladder cancer: so many drugs, so little progress: what's wrong with this picture? Cancer 2008, 113:1275-1277.
3. Mani SA, Guo W, Liao M-J, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M: The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008, 133:704-715.
4. Singh S, Sadacharan S, Su S, Belldegrun A, Persad S, Singh G: Overexpression of vimentin role in the invasive phenotype in an Androgen-independent model of prostate cancer. Cancer Res 2003, 63:2306-2311.
5. Thiery JP: Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002, 2:442-454.
6. Angst BD, Marcozzi C, Magee AI: The cadherin superfamily. J Cell Sci 2001, 114:625-626.
7. Kang Y, Massague J: Epithelial-mesenchymal transitions: twist in development and metastasis. Cell 2004, 118:277-279.
8. Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297.
9. Lee EJ, Gusev Y, Jiang J, Nuovo GJ, Lerner MR, Frankel WL, Morgan DL, Postier RG, Brackett DJ, Schmittgen TD: Expression profiling identifies microRNA signature in pancreatic cancer. Int J Cancer 2007, 120:1046-1054.
10. Cortez MA, Ivan C, Zhou P, Wu X, Ivan M, Calin GA: microRNAs in cancer: from bench to bedside. Adv Cancer Res 2010, 108:113-157.
11. Hoshino I, Matsubara H: MicroRNAs in cancer diagnosis and therapy: from bench to bedside. Surg Today 2013, 43:467-478.
12. Fabbri M, Calin GA: Epigenetics and miRNAs in human cancer. Adv Genet 2010, 70:87-99.
13. Ferdin J, Kunej T, Calin GA: Non-coding RNAs: identification of cancerassociated microRNAs by gene profiling. Technol Cancer Res Treat 2010, 9:123-138.
14. Le XF, Merchant O, Bast RC, Calin GA: The roles of MicroRNAs in the cancer invasion-metastasis cascade. Cancer Microenviron 2010, 3:137-147.
15. Hurteau GJ, Carlson JA, Spivack SD, Brock GJ: Overexpression of the microRNA hsa-miR-200c leads to reduced expression of transcription factor 8 and increased expression of E-cadherin. Cancer Res 2007, 67:7972-7976.
16. Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, Vadas MA, Khew-Goodall Y, Goodall GJ: The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 2008, 10:593-601.
17. Korpal M, Lee ES, Hu G, Kang Y: The miR-200 family inhibits epithelialmesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem 2008, 283:14910-14914.
18. Shimono Y, Zabala M, Cho RW, Lobo N, Dalerba P, Qian D, Diehn M, Liu H, Panula SP, Chiao E, Dirbas FM, Somlo G, Pere RAR, Lao K, Clarke MF: Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell 2009, 138:592-603.
19. Leskelä S, Leandro-García LJ, Mendiola M, Barriuso J, Inglada-Pérez L, Muñoz I, Martínez-Delgado B, Redondo A, de Santiago J, Robledo M: The miR-200 family controls β-tubulin III expression and is associated with paclitaxelbased treatment response and progression-free survival in ovarian cancer patients. Endocr Relat Cancer 2011, 18:85-95.
20. Vallejo DM, Caparros E, Dominguez M: Targeting notch signalling by the conserved miR-8/200 microRNA family in development and cancer cells. EMBO J 2011, 30:756-769.
21. Lee JW, Park YA, Choi JJ, Lee YY, Kim CJ, Choi C, Kim TJ, Lee NW, Kim BG, Bae DS: The expression of the miRNA-200 family in endometrial endometrioid carcinoma. Gynecol Oncol 2011, 120:56-62.
22. Dykxhoorn DM: MicroRNAs and metastasis: little RNAs go a long way. Cancer Res 2010, 70:6401-6406.
23. Park SM, Gaur AB, Lengyel E, Peter ME: The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev 2008, 22:894-907.
24. Hsu M-Y, Meier FE, Nesbit M, Hsu J-Y, Van Belle P, Elder DE, Herlyn M: E-cadherin expression in melanoma cells restores keratinocyte-mediated growth control and down-regulates expression of invasion-related adhesion receptors. Am J Pathol 2000, 156:1515-1525.
25. Tucci M, Lucarini G, Brancorsini D, Zizzi A, Pugnaloni A, Giacchetti A, Ricotti G, Biagini G: Involvement of E-cadherin, β-catenin, Cdc42 and CXCR4 in the progression and prognosis of cutaneous melanoma. British J Dermatol 2007, 157:1212-1216.
26. Calin GA, Croce CM: MicroRNA signatures in human cancers. Nat Rev Cancer 2006, 6:857-866.
27. Jacobs JJ, van Lohuizen M: Polycomb repression: from cellular memory to cellular proliferation and cancer. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer 2002, 1602:151-161.
28. Piunti A, Pasini D: Epigenetic factors in cancer development: polycomb group proteins. Future Oncol 2011, 7:57-75.
29. Jacobs JJ, Kieboom K, Marino S, DePinho RA, van Lohuizen M: The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus. Nature 1999, 397:164-168.
30. Jacobs JJ, Scheijen B, Voncken J-W, Kieboom K, Berns A, van Lohuizen M: Bmi-1 collaborates with c-Myc in tumorigenesis by inhibiting c-Myc-induced apoptosis via INK4a/ARF. Genes Dev 1999, 13:2678-2690.
31. Kim JH, Yoon SY, Kim C-N, Joo JH, Moon SK, Choe IS, Choe Y-K, Kim JW: The Bmi-1 oncoprotein is overexpressed in human colorectal cancer and correlates with the reduced p16INK4a/p14ARF proteins. Cancer Lett 2004, 203:217-224.
32. Sherr CJ: The INK4a/ARF network in tumour suppression. Nat Rev Mol Cell Biol 2001, 2:731-737.
33. Molofsky AV, Pardal R, Iwashita T, Park I-K, Clarke MF, Morrison SJ: Bmi-1 dependence distinguishes neural stem cell self-renewal from progenitor proliferation. Nature 2003, 425:962-967.
34. Mihic-Probst D, Kuster A, Kilgus S, Bode-Lesniewska B, Ingold-Heppner B, Leung C, Storz M, Seifert B, Marino S, Schraml P: Consistent expression of the stem cell renewal factor BMI-1 in primary and metastatic melanoma. Int J Cancer 2007, 121:1764-1770.
35. Qin Z-K, Yang J-A, Ye Y-l, Zhang X, Xu L-H, Zhou F-J, Han H, Liu Z-W, Song L-B, Zeng M-S: Expression of Bmi-1 is a prognostic marker in bladder cancer. BMC Cancer 2009, 9:61.
36. Humbert PO, Verona R, Trimarchi JM, Rogers C, Dandapani S, Lees JA: E2f3 is critical for normal cellular proliferation. Genes Dev 2000, 14:690-703.
37. Welch C, Chen Y, Stallings R: MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells. Oncogene 2007, 26:5017-5022.
38. Sylvestre Y, De Guire V, Querido E, Mukhopadhyay UK, Bourdeau V, Major F, Ferbeyre G, Chartrand P: An E2F/miR-20a autoregulatory feedback loop. J Biol Chem 2007, 282:2135-2143.
39. Huang L, Luo J, Cai Q, Pan Q, Zeng H, Guo Z, Dong W, Huang J, Lin T: MicroRNA-125b suppresses the development of bladder cancer by targeting E2F3. Int J Cancer 2011, 128:1758-1769.
40. Olsson AY, Feber A, Edwards S, Te Poele R, Giddings I, Merson S, Cooper CS: Role of E2F3 expression in modulating cellular proliferation rate in human bladder and prostate cancer cells. Oncogene 2007, 26:1028-1037.
41. Feber A, Clark J, Goodwin G, Dodson AR, Smith PH, Fletcher A, Edwards S, Flohr P, Falconer A, Roe T, Kovacs G, Dennis N, Fisher C, Wooster R, Huddart R, Foster CS, Cooper CS: Amplification and overexpression of E2F3 in human bladder cancer. Oncogene 2004, 23:1627-1630.
42. Yu J, Ohuchida K, Mizumoto K, Sato N, Kayashima T, Fujita H, Nakata K, Tanaka M: Research MicroRNA, hsa-miR-200c, is an independent prognostic factor in pancreatic cancer and its upregulation inhibits pancreatic cancer invasion but increases cell proliferation. Cancer Res 2010, 12:13.
43. Liu X-G, Zhu W-Y, Huang Y-Y, Ma L-N, Zhou S-Q, Wang Y-K, Zeng F, Zhou J-H, Zhang Y-K: High expression of serum miR-21 and tumor miR-200c associated with poor prognosis in patients with lung cancer. Med Oncol 2012, 29:618-626.
44. Liu S, Tetzlaff MT, Cui R, Xu X: miR-200c inhibits melanoma progression and drug resistance through down-regulation of Bmi-1. Am J Pathol 2012, 181:1823-1835.
45. Boominathan L: The tumor suppressors p53, p63, and p73 are regulators of microRNA processing complex. PLoS One 2010, 5:e10615.
46. Chang C-J, Chao C-H, Xia W, Yang J-Y, Xiong Y, Li C-W, Yu W-H, Rehman SK, Hsu JL, Lee H-H: p53 regulates epithelial-mesenchymal transition and stem cell properties through modulating miRNAs. Nat Cell Biol 2011, 13:317-323.
47. Alajez N, Shi W, Hui A, Yue S, Ng R, Lo K, Bastianutto C, O'sullivan B, Gullane P, Liu F: Targeted depletion of BMI1 sensitizes tumor cells to P53-mediated apoptosis in response to radiation therapy. Cell Death Differ 2009, 16:1469-1479.
48. Calao M, Sekyere E, Cui H, Cheung B, Thomas W, Keating J, Chen J, Raif A, Jankowski K, Davies N: Direct effects of Bmi1 on p53 protein stability inactivates oncoprotein stress responses in embryonal cancer precursor cells at tumor initiation. Oncogene 2013, 32:3616-3626.
49. Lukas J, Parry D, Aagaard L, Mann DJ, Bartkova J, Strauss M, Peters G, Bartek J: Retinoblastoma-Protein-Dependent Cell-Cycle Inhibition by the Tumour Suppressor p16. 1995.
50. Zhang Y, Xiong Y, Yarbrough WG: ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 1998, 92:725-734.
51. Leone G, DeGregori J, Yan Z, Jakoi L, Ishida S, Williams RS, Nevins JR: E2F3 activity is regulated during the cell cycle and is required for the induction of S phase. Genes Dev 1998, 12:2120-2130.
52. Korpal M, Kang Y: The emerging role of miR-200 family of microRNAs in epithelial-mesenchymal transition and cancer metastasis. RNA Biol 2008, 5:115-119.
53. Tryndyak VP, Beland FA, Pogribny IP: E-cadherin transcriptional downregulation by epigenetic and microRNA-200 family alterations is related to mesenchymal and drug-resistant phenotypes in human breast cancer cells. Int J Cancer 2010, 126:2575-2583.